LBP02 / Xbiome - LARVOL DELTA

Population genetic structure of Aedes aegypti subspecies in selected geographical locations in Sudan. (PubMed, Sci Rep) - "Hardy-Weinberg Equilibrium (HWE) for the two subspecies revealed that Aaa deviated from HWE among the seven microsatellite loci, while Aaf exhibited departure in five loci and no departure in two loci (A10 and M201)...aegypti subspecies population and the gene flow among them, which may be interpreted as the mosquito vector's capacity for dispersal, were revealed in this study. These findings will help in the improvement of dengue epidemiology research including information on the identity of the target vector/subspecies and the arboviruses vector surveillance program."

Journal • Dengue Fever

An efficient method for screening rice breeding lines against races of Magnaporthe oryzae. (PubMed, Plant Dis) - "The varieties M201, Cheniere, and Frontier were highly susceptible (score 6; 100% disease) to the race IE1-K...Taken together, our data proved that the 0-6 blast scale can efficiently determine the resistance levels of rice varieties against major blast races. This robust method will assist rice breeding programs to incorporate durable resistance against major and emerging blast races."

Journal

Beneficial Effects of Two Marine Oxygen Carriers, M101 and M201, on Human Islet Quality in Hypoxic Culture Conditions. (PubMed, Cell Transplant) - "Human islet function or viability was improved in vitro in the presence of these oxygen carriers. Thus, the utilization of M101 or M201 could be a safe and easy way to improve human islet oxygenation and survival in hypoxic conditions as observed during islet culture prior to transplantation or islet encapsulation."

Journal • Transplantation

Development and Validation of Diagnostic KASP Markers for Brown Planthopper Resistance in Rice. (PubMed, Front Genet) - "Bph17 and Bph32 genes that are highly effective against the biotype 4 of the BPH have been validated by gene specific SNPs with favorable alleles in M201, M272, M344, RathuHeenati, and RathuHeenati accession. These identified genotypes could be useful as donors for transferring BPH resistance into popular varieties with marker-assisted selection using these diagnostic SNPs. The resistant lines and the significant SNPs unearthed from our study can be useful in developing BPH-resistant varieties after validating them in biparental populations with the potential usefulness of SNPs as causal markers."

Journal

Gender and Racial Disparities in Faculty Rank and Leadership Positions Among Stem Cell Transplant Physicians in the United States (TCT-ASTCT-CIBMTR 2022) - "For example, within the field of hematology/oncology, though women make up between 40 and 49 percent of first-year fellows, they constitute less than 40 percent of the practicing academic hematology/oncology workforce and less than a third of leadership positions (ABIM 2018, Riaz et al... Gender and racial disparity exist in faculty rank and leadership positions among Stem cell Transplant physicians in the United States. Major limitation of our study is that online data from public sources could be incomplete or not updated. Further investigation is required to validate our results from membership databases available in professional societies."

Bone Marrow Transplantation • Hematological Disorders • Oncology • Pediatrics • Transplantation

Xbiome Acquires Clinical-Stage Program Targeting Ulcerative Colitis (Businesswire) - "Xbiome Inc...announced that it has acquired the clinical-stage M201 program from Assembly Biosciences, Inc., a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus and other viral diseases. The M201 program is designed for patients with mild to moderate ulcerative colitis....Xbiome is expected to commence the M201 Phase 1b clinical trial in 2022 in the US and the program will become part of Xbiome’s Global Innovation Center, where Xbiome will work closely with its global technology team in Europe and Asia in order to enhance and support the continued development of M201."

M&A • New P1 trial • Inflammatory Bowel Disease • Ulcerative Colitis

"Place your order and get your stuff ready👈 #HIC18 #abimf2018 #ANMS18 #WE2012 #MOGA18 #AFibPatient18 #AAFPNC #AAPM2018 #AANAM #PHASA2018 #BCVS18 #47MillerMed #ASH17 #BCSM #HCLDR #HITsm #hpm #LCSM #BTSM #hcsmSA #JACR #NephJC #ASEchoJC #SPSM #NurChat" (@DoctorJ11480258)

Clinical • Breast Cancer • CNS Disorders • Lung Cancer • Solid Tumor

"Health Benefits Of Mushroom Coffee: 👉 https://t.co/8nq5xRCARv 👈 #HIC18 #abimf2018 #ANMS18 #WE2012 #MOGA18 #AFibPatient18 #AAFPNC #AAPM2018 #AANAM #PHASA2018 #BCVS18 #47MillerMed #ASH17 #BCSM #HCLDR #HITsm #hpm #LCSM #BTSM #hcsmSA #JACR #NephJC #ASEchoJC #SPSM #NurChat" (@Thaha89164523)

Clinical • Breast Cancer • CNS Disorders • Lung Cancer • Solid Tumor

"#HIC18 #abimf2018 #ANMS18 #WE2012 #MOGA18 #AFibPatient18 #AAFPNC #AAPM2018 #AANAM #PHASA2018 #OchreDay2018 #BCVS18 #JergeDental #47MillerMed #ASH17NEW #OW2018 #MonitoreoHem2018 #OCEIONonClinModels #MEWomenshealth #EAHM2018 https://t.co/7OnvgEPv9X" (@healthavenues)

Clinical • CNS Disorders • Women's Health

Genetic insights into the paternal admixture history of Chinese Mongolians via high-resolution customized Y-SNP SNaPshot panels. (PubMed, Forensic Sci Int Genet) - "We also observed DE-M145, D1*-M174, C1*-F3393, G*-M201, I-M170, J*-M304, L-M20, O1a*-M119, and Q*-M242 at relatively low frequencies (< 5.00%), suggesting a complex admixture history between Mongolians and other incoming Eurasians from surrounding regions. Genetic clustering analyses indicated that the studied Mongolians showed close genetic affinities with other Altaic-speaking populations and Sinitic-speaking Hui people. The Y-SNP haplotype/haplogroup-based genetic legacy not only revealed that the stratification among geographically/linguistically/ethnically different Chinese populations was highly consistent with the geographical division and language classification, but also demonstrated that patrilineal genetic materials could provide fine-scale genetic structures among geographically different Mongolian people, suggesting that our developed high-resolution Y-SNP SNaPshot panels have the potential for forensic pedigree searches and biogeographical ancestry..."

Journal

Phylogenetic history of patrilineages rare in northern and eastern Europe from large-scale re-sequencing of human Y-chromosomes. (PubMed, Eur J Hum Genet) - "We construct dated phylogenies for haplogroups E2-M215, J2-M172, G-M201 and Q-M242 on the basis of 421 (of them 282 novel) high-coverage chrY sequences collected from large-scale databases focusing on populations of NEE. We assess the possible direction of influx of ancestral carriers for some of these male lineages. In addition, we demonstrate the congruency of paternal haplogroup composition of our dataset with two independent population-based cohorts from Estonia and Sweden."

Journal

"#BCSM #MedEd #HCLDR #HITsm #hpm #LCSM #BTSM #hcsmSA #JACR #NephJC #ASEchoJC #SPSM #NurChat #KareoChat #EofL #Path2Path #LaMPSCymru #HealthyMindChat #PubertyEndoChat #JJDiabetesInst #HIC18 #abimf2018 #ANMS18 #WE2012 #MOGA18 #AFibPatient18 #AAFPNC #AAPM2018 #AANAM #PHASA2018 #India" (@lokeshunbreaka1)

Clinical • Breast Cancer • CNS Disorders • Lung Cancer • Metabolic Disorders • Solid Tumor

ABI-M201 in Adult Subjects With Mildly-to-Moderately Active Ulcerative Colitis (clinicaltrials.gov) - P1b; N=15; Terminated; Sponsor: Assembly Biosciences; N=44 ➔ 15; Trial completion date: Mar 2023 ➔ Jan 2021; Recruiting ➔ Terminated; Trial primary completion date: Aug 2022 ➔ Jan 2021; Sponsor Decision

Clinical • Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

"#BCSM #MedEd #HCLDR #HITsm #hpm #LCSM #BTSM #hcsmSA #JACR #NephJC #ASEchoJC #SPSM #NurChat #KareoChat #EofL #Path2Path #LaMPSCymru #HealthyMindChat #PubertyEndoChat #JJDiabetesInst #HIC18 #abimf2018 #ANMS18 #WE2012 #MOGA18 #AFibPatient18 #AAFPNC #AAPM2018 #AANAM #PHASA2018" (@Ancient_Ink)

Clinical • Breast Cancer • CNS Disorders • Lung Cancer • Metabolic Disorders • Oncology • Solid Tumor

"#BCSM #MedEd #HCLDR #HITsm #hpm #LCSM #BTSM #hcsmSA #JACR #NephJC #ASEchoJC #SPSM #NurChat #KareoChat #EofL #Path2Path #LaMPSCymru #HealthyMindChat #PubertyEndoChat #JJDiabetesInst #HIC18 #abimf2018 #ANMS18 #WE2012 #MOGA18 #AFibPatient18 #AAFPNC #AAPM2018 #AANAM #PHASA2018" (@SM141990)

Clinical • Breast Cancer • CNS Disorders • Lung Cancer • Metabolic Disorders • Oncology • Solid Tumor

ABI-M201 in Adult Subjects With Mildly-to-Moderately Active Ulcerative Colitis (clinicaltrials.gov) - P1b; N=44; Recruiting; Sponsor: Assembly Biosciences; Trial completion date: Dec 2021 ➔ Mar 2023; Trial primary completion date: Jun 2021 ➔ Aug 2022

Clinical • Trial completion date • Trial primary completion date • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

"निकाले पाइल्स का दम - एनाफाइन मरहम #Path2Path #LaMPSCymru #HealthyMindChat #PubertyEndoChat #JJDiabetesInst #HIC18 #abimf2018 #ANMS18 #WE20 #MOGA18 #AFibPatient18 #AAFPNC #AAPM2018 #AANAM #PHASA2018 #OchreDay2018 #BCVS18 #JergeDental #47MillerMed #ASH17 #OW2018 #MonitoreoHem2018" (@FinemorningPh)

Clinical • CNS Disorders • Metabolic Disorders

Preclinical data from Assembly Biosciences’ microbiome program in ulcerative colitis featured in DDW 2020 virtual meeting portal and upcoming journal supplements (GlobeNewswire, Assembly Biosciences, Inc.) - "Assembly Biosciences, Inc....today announced that the abstract accepted as an ePoster presentation at Digestive Disease Week (DDW) 2020 Virtual Meeting may now be viewed at the online meeting portal....'We are pleased that these important preclinical data supporting our lead clinical-stage candidate ABI-M201 were selected for presentation'...'These data showcase the strength of our live microbial biotherapeutic discovery platform to develop well-defined consortia of bacteria, rationally selected based on disease-relevant mechanisms.'"

Preclinical • Gastroenterology • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

Title: Developmental validation of Y-SNP pedigree tagging system: A panel via quick ARMS PCR. (PubMed, Forensic Sci Int Genet) - "The panel precisely defines the 11 haplogroups (E-M96, D-JST021355, N-M231, C-M130, O-P186, I-M170, IJ-M429, K-M9, QR-M45, G-M201, and IJK-M522) and 13 sub-haplogroups (D1a1a1-N1, D1a2a-P47, C2-M217, N1a1-M46, O1a-M119, O1b-M268, O1b2-M176, O2-M122, O2a1-KL1, O2a2-P201, O2a2b-P164, O2a2a1a2-M7 and O2a2b1a1-M117)...In this study, we try to discriminate the suspect's pedigree on the level of Y-SNP haplogroups. These results show that Y-SNP Pedigree Tagging System is a robust and reliable amplification kit which can be used for male haplogroup determination."

Journal

"https://t.co/hY2njVuo0G #HIC18 #abimf2018 #ANMS18 #WE2012 #MOGA18 #AFibPatient18 #AAFPNC #AAPM2018 #AANAM #PHASA2018 #OchreDay2018 #BCVS18 #JergeDental #47MillerMed #ASH17 https://t.co/hY2njVuo0G" (@dr20082009)

Clinical

Assembly Biosciences Announces Appointment of John McHutchison, AO, MD, as President and Chief Executive Officer (GlobeNewswire, Assembly Biosciences, Inc.) - “As we now have four development candidates across our HBV programs and microbiome platform, including our lead core inhibitor ABI-H0731 completing its Phase 2 studies and ABI-M201 in a Phase 1b study for ulcerative colitis, it is an ideal time to pass the torch to...

Clinical • Regulatory

"Honored to participate in this years conference on (Re)Building Trust! #ABIMF2019 @WolfsonD @RichardBaron17 @ABIMFoundation @FutureDocs @neel_shah @ChrisMoriates @sacjai @bhangrajay @DhruvKhullar" (@ReshmaGuptaMD)

Assembly Biosciences Announces First Patient Dosed with ABI-M201 in Phase 1b Clinical Trial for Mildly to Moderately Active Ulcerative Colitis (GlobeNewswire, Assembly Biosciences, Inc.) - ABI-M201 utilizes Assembly’s proprietary and patented Gemicel® capsule-in-capsule delivery system for targeted delivery into the GI tract. ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced the initiation of dosing in a Phase 1b clinical trial to evaluate ABI-M201 (M201) in patients with mildly to moderately active ulcerative colitis (UC).

Clinical • Enrollment status • Preclinical

Assembly Biosciences Announces First Patient Dosed with ABI-M201 in Phase 1b Clinical Trial for Mildly to Moderately Active Ulcerative Colitis (GlobeNewswire, Assembly Biosciences, Inc.) - "Assembly Biosciences...announced the initiation of dosing in a Phase 1b clinical trial to evaluate ABI-M201 (M201) in patients with mildly to moderately active ulcerative colitis (UC)."

Clinical • Enrollment status • Preclinical

Newly added product (GlobeNewswire) - P1, Inflammatory bowel disease

Pipeline update